COMPANY SUMMARY
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Financial Summary
| Share Statistics |
NTRA |
Industry Median |
Percentile (All Stocks) |
| Market Cap (Mil) |
$46,823.8 |
$286.3 |
93% |
|
| Shares Out (Mil) |
143.3 |
54.2 |
70% |
|
| Institutional Ownership |
97.1% |
92.8% |
72% |
|
| Float (Mil) |
139.9 |
39.7 |
67% |
|
| Beta |
1.51 |
0.94 |
84% |
|
| Avg Daily Volume (000s) |
1,676 |
534 |
79% |
|
Price Change (52-week) |
102.9% |
58.7% |
91% |
|
| Growth |
NTRA |
Industry Median |
Percentile (All Stocks) |
| Sales (5yr) |
42.6% |
13.6% |
94% |
|
| Net Income (5yr) |
1.9% |
(10.1%) |
42% |
|
| EPS (5yr) |
11.7% |
16.0% |
50 |
|
| Dividends (5yr) |
0.0% |
0.0% |
0% |
|
| Cash Flow (5yr) |
51.3% |
(15.6%) |
93% |
|
| Estimates |
Qtrly |
Current Fiscal Year |
Next Fiscal Year |
| # of Estimates |
14 |
15 |
15 |
| Current EPS |
($0.244) |
($1.394) |
($0.089) |
| Month Ago EPS |
($0.378) |
($1.709) |
($0.205) |
| # Rev Up |
0 |
1 |
1 |
| # Rev Down |
1 |
0 |
0 |
| Three Months Ago EPS |
($0.352) |
($1.655) |
($0.338) |
| Year/Year Chg |
(47.8%) |
(8.5%) |
(216.7%) |
| Financials |
NTRA |
Industry Median |
Percentile (All Stocks) |
| Sales (TTM) (Mil) |
$2,707 |
$37 |
65% |
|
| Net Income (TTM) (Mil) |
($192) |
($43) |
7% |
|
| EPS (TTM) |
($1.373) |
($1.400) |
18% |
|
| Operating Cash Flow (TTM) (Mil) |
$228 |
($31) |
61% |
|
| Net Cash Flow (TTM) (Mil) |
$92 |
$2 |
76% |
|
| Long-Term Debt (Q1) (Mil) |
$143 |
$4 |
47% |
|
| Enterprise Value (Q1) (Mil) |
$45,576 |
$160 |
91% |
|
| Valuation |
NTRA |
Industry Median |
Percentile (All Stocks) |
| P/B |
25.62 |
2.77 |
97% |
|
| P/E |
na |
19.1 |
na |
|
| Dividend Yield |
0.0% |
0.0% |
0% |
|
| PEG (5yr hist) |
na |
1.0 |
na |
|
| Ratios |
NTRA |
Industry Median |
Percentile (All Stocks) |
| Gross Margin |
65.2% |
64.2% |
77% |
|
| Net Margin |
(7.1%) |
(75.9%) |
23% |
|
| ROA |
(8.7%) |
(47.3%) |
26% |
|
| ROE |
(12.5%) |
(55.0%) |
27% |
|
| Liabilities to Assets |
31.5% |
29.6% |
23% |
|
| F-Score |
5 |
2 |
50% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
NTRA meetings the criteria of 2 screen:
Stock Screen
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
FACTOR STRATEGY
Est Rev: Up 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.